The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with shared decision-making and PSA-testosterone co-monitoring as the foundation of responsible care, as Helen L. Bernie, DO, MPH, outlines in this interview.
Helen L. Bernie, DO, MPH, discusses how expanded TRT labeling could improve care for men with idiopathic hypogonadism.
Exogenous testosterone therapy and fertility are fundamentally incompatible.
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
"I hope that these new guidelines and the removal of the black box warning on testosterone therapy will help more physicians feel comfortable providing testosterone therapy to men," says Helen L. Bernie, DO, MPH.
"I think that testosterone is really a medication that can be life changing for so many men, says Helen L. Bernie, DO, MPH.
"I'm so excited about them finally removing this boxed warning," says Helen L. Bernie, DO, MPH.
"This has been exciting from a physician-surgeon standpoint," says Helen L. Bernie, DO, MPH.
"I cannot wait to see what the SMSNA is going to have in store next year," says Helen L. Bernie, DO, MPH.
